Changes to UK Statutory Scheme go ahead despite pharma criticism
Drug Discovery World
DECEMBER 6, 2023
It intends to set amended payment percentages for 2024 to 2026 based on an allowed growth rate that has been increased to 2%. This means that companies will pay a rebate on the sales of branded medicines to the NHS of 21.9% before this year, according to the Association of the British Pharmaceutical Industry (ABPI).
Let's personalize your content